Abstract: Provided are methods for determining the presence or absence of donor specific antibodies in a biological sample. The methods include mixing a cellular sample from a donor with a biological sample from a recipient under conditions sufficient for recipient immune antibodies, if present, to bind to donor cell surface antigen (Ag) to form an immune antibody-Ag complex, contacting the mixture with beads comprising an antibody that specifically binds the immune antibody-Ag complex (e.g., the Ag or immune antibody) on a surface thereof, adding under lysis conditions a detectably-labeled antibody that specifically binds the immune antibody-Ag complex bound to the beads, and detecting the presence or absence of the detectably-labeled antibody bound to the immune antibody-Ag complex to determine the presence or absence of donor specific antibodies in the biological sample from the recipient. Systems and kits for practicing the subject methods are also provided.

Abstract: Aspects of the present disclosure include methods that include co-culturing a cell and a microparticle that includes a capture ligand, in a culture medium under conditions in which a biomarker produced by the cell is bound by the capture ligand. Such methods may further include detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent. The methods may further include determining the proportion or number of cells among a heterogeneous cell population that produced the biomarker and/or the level of biomarker secreted by such cells. Compositions, systems and kits are also provided.

Abstract: Aspects of the present disclosure include methods that include co-culturing a cell and a microparticle that includes a capture ligand, in a culture medium under conditions in which a biomarker produced by the cell is bound by the capture ligand. Such methods may further include detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent. The methods may further include determining the proportion or number of cells among a heterogeneous cell population that produced the biomarker and/or the level of biomarker secreted by such cells. Compositions, systems and kits are also provided.

Abstract: Provided are methods for determining the presence or absence of donor specific antibodies in a biological sample. The methods include mixing a cellular sample from a donor with a biological sample from a recipient under conditions sufficient for recipient immune antibodies, if present, to bind to donor cell surface antigen (Ag) to form an immune antibody-Ag complex, contacting the mixture with beads comprising an antibody that specifically binds the immune antibody-Ag complex (e.g., the Ag or immune antibody) on a surface thereof, adding under lysis conditions a detectably-labeled antibody that specifically binds the immune antibody-Ag complex bound to the beads, and detecting the presence or absence of the detectably-labeled antibody bound to the immune antibody-Ag complex to determine the presence or absence of donor specific antibodies in the biological sample from the recipient. Systems and kits for practicing the subject methods are also provided.

Abstract: Aspects of the present disclosure include methods that include co-culturing a cell and a microparticle that includes a capture ligand, in a culture medium under conditions in which a biomarker produced by the cell is bound by the capture ligand. Such methods may further include detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent. The methods may further include determining the proportion or number of cells among a heterogeneous cell population that produced the biomarker and/or the level of biomarker secreted by such cells. Compositions, systems and kits are also provided.

Abstract: Provided are methods for determining the presence or absence of donor specific antibodies in a biological sample. The methods include mixing a cellular sample from a donor with a biological sample from a recipient under conditions sufficient for recipient immune antibodies, if present, to bind to donor cell surface antigen (Ag) to form an immune antibody-Ag complex, contacting the mixture with beads comprising an antibody that specifically binds the immune antibody-Ag complex (e.g., the Ag or immune antibody) on a surface thereof, adding under lysis conditions a detectably-labeled antibody that specifically binds the immune antibody-Ag complex bound to the beads, and detecting the presence or absence of the detectably-labeled antibody bound to the immune antibody-Ag complex to determine the presence or absence of donor specific antibodies in the biological sample from the recipient. Systems and kits for practicing the subject methods are also provided.

Abstract: Aspects of the present disclosure include methods that include co-culturing a cell and a microparticle that includes a capture ligand, in a culture medium under conditions in which a biomarker produced by the cell is bound by the capture ligand. Such methods may further include detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent. The methods may further include determining the proportion or number of cells among a heterogeneous cell population that produced the biomarker and/or the level of biomarker secreted by such cells. Compositions, systems and kits are also provided.

Abstract: The invention provides methods for sensitive and specific detection of complement fixing antibodies in a biological sample using complement factor C1q, including autologous complement factor C1q present in the biological sample and a detectably labeled antibody that binds the autologous complement factor C1q, exogenous human complement factor C1q and a detectably labeled antibody that binds the exogenous human complement factor C1q, detectably labeled exogenous human complement factor C1q, or a combination of autologous complement factor C1q and exogenous human complement factor C1q. The invention also features kits, systems, and devices for use in the methods of the invention.

Abstract: Provided are methods for determining the presence or absence of donor specific antibodies in a biological sample. The methods include mixing a cellular sample from a donor with a biological sample from a recipient under conditions sufficient for recipient immune antibodies, if present, to bind to donor cell surface antigen (Ag) to form an immune antibody-Ag complex, contacting the mixture with beads comprising an antibody that specifically binds the immune antibody-Ag complex (e.g., the Ag or immune antibody) on a surface thereof, adding under lysis conditions a detectably-labeled antibody that specifically binds the immune antibody-Ag complex bound to the beads, and detecting the presence or absence of the detectably-labeled antibody bound to the immune antibody-Ag complex to determine the presence or absence of donor specific antibodies in the biological sample from the recipient. Systems and kits for practicing the subject methods are also provided.

Abstract: Provided are methods for determining the presence or absence of donor specific antibodies in a biological sample. The methods include mixing a cellular sample from a donor with a biological sample from a recipient under conditions sufficient for recipient immune antibodies, if present, to bind to donor cell surface antigen (Ag) to form an immune antibody-Ag complex, contacting the mixture with beads comprising an antibody that specifically binds the immune antibody-Ag complex (e.g., the Ag or immune antibody) on a surface thereof, adding under lysis conditions a detectably-labeled antibody that specifically binds the immune antibody-Ag complex bound to the beads, and detecting the presence or absence of the detectably-labeled antibody bound to the immune antibody-Ag complex to determine the presence or absence of donor specific antibodies in the biological sample from the recipient. Systems and kits for practicing the subject methods are also provided.

Abstract: Aspects of the present disclosure include methods that include co-culturing a cell and a microparticle that includes a capture ligand, in a culture medium under conditions in which a biomarker produced by the cell is bound by the capture ligand. Such methods may further include detecting (e.g., by flow or mass cytometry) complexes that include the microparticle, the capture ligand, the biomarker, and a detection reagent. The methods may further include determining the proportion or number of cells among a heterogeneous cell population that produced the biomarker and/or the level of biomarker secreted by such cells. Compositions, systems and kits are also provided.

Abstract: Provided are methods for simultaneously determining the presence or absence of complement-fixing antibody (CFAb) and non-complement-fixing antibody (non-CFAb) in a biological sample in a single reaction. The methods include mixing a cellular sample from a donor, a biological sample from a recipient, isolated human complement component C1q (C1q), and a labeled C1q binding agent (CBA), under conditions sufficient for recipient CFAb and non-CFAb, if present, to bind to donor cell surface antigen (Ag) to form antibody-Ag (Ab-Ag-C1q-CBA) complexes. The methods further include contacting the mixture with labeled an-ti-hIgG antibodies and labeled anti-CD antibodies, and detecting (e.g., semi-quantitatively) the presence or absence of the detectable labels bound to the antibody-Ag complexes to determine the presence or absence of CFAb and non-CFAb in a biological sample from the recipient. Systems and kits for practicing the subject methods are also provided.

Abstract: Provided are methods for determining the presence or absence of donor specific antibodies in a biological sample. The methods include mixing a cellular sample from a donor with a biological sample from a recipient under conditions sufficient for recipient immune antibodies, if present, to bind to donor cell surface antigen (Ag) to form an immune antibody-Ag complex, contacting the mixture with beads comprising an antibody that specifically binds the immune antibody-Ag complex (e.g., the Ag or immune antibody) on a surface thereof, adding under lysis conditions a detectably-labeled antibody that specifically binds the immune antibody-Ag complex bound to the beads, and detecting the presence or absence of the detectably-labeled antibody bound to the immune antibody-Ag complex to determine the presence or absence of donor specific antibodies in the biological sample from the recipient. Systems and kits for practicing the subject methods are also provided.

Abstract: The invention provides methods for sensitive and specific detection of complement fixing antibodies in a biological sample using complement factor C1q, including autologous complement factor C1q present in the biological sample and a detectably labeled antibody that binds the autologous complement factor C1q, exogenous human complement factor C1q and a detectably labeled antibody that binds the exogenous human complement factor C1q, detectably labeled exogenous human complement factor C1q, or a combination of autologous complement factor C1q and exogenous human complement factor C1q. The invention also features kits, systems, and devices for use in the methods of the invention.

Abstract: Methods are provided for transplanting a histoincompatible organ allograft in a subject, methods for enhancing organ allograft survival in a subject, methods for reducing the amount of anti-HLA alloantibodies in a transplant candidate and methods to make candidate less susceptible to rejection.

Abstract: A composition for modulating immune response in mammals, comprises a therapeutic agent such as a stereoisomer of inositol, derivatives, salts, and mixtures thereof, and optionally a carrier. The composition is provided in solid and liquid formulations, including solutions, suspensions, spreadable and solid forms, as an implant, inhalant, and in vaporizable, injectable, oral and transdermal forms, and the like. The composition of the invention is useful for modulating (enhancing/inhibiting) the immune response. The therapeutic agent of this invention enhances/suppresses B and/or T lymphocyte activity(ies) in normal, aging and immunodeficient mammals, as well as those afflicted with auto-immune disease (s), or subjected to transplants.

Abstract: In accordance with the present invention, there are provided isolated nucleic acids useful in diagnostic methods and kits for detecting a genetic predisposition for seronegative spondyloarthropathies.